CN113582889B - 磺酰脲和相关化合物及其用途 - Google Patents

磺酰脲和相关化合物及其用途 Download PDF

Info

Publication number
CN113582889B
CN113582889B CN202110867103.8A CN202110867103A CN113582889B CN 113582889 B CN113582889 B CN 113582889B CN 202110867103 A CN202110867103 A CN 202110867103A CN 113582889 B CN113582889 B CN 113582889B
Authority
CN
China
Prior art keywords
disease
mmol
disorder
condition
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110867103.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113582889A (zh
Inventor
卢克·奥尼尔
丽贝卡·科尔
马修·库珀
埃夫里尔·罗伯逊
凯特·施罗德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Original Assignee
University of Queensland UQ
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56691944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113582889(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2015900507A external-priority patent/AU2015900507A0/en
Application filed by University of Queensland UQ, College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin filed Critical University of Queensland UQ
Priority to CN202110867103.8A priority Critical patent/CN113582889B/zh
Publication of CN113582889A publication Critical patent/CN113582889A/zh
Application granted granted Critical
Publication of CN113582889B publication Critical patent/CN113582889B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/56—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
CN202110867103.8A 2015-02-16 2016-02-16 磺酰脲和相关化合物及其用途 Active CN113582889B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110867103.8A CN113582889B (zh) 2015-02-16 2016-02-16 磺酰脲和相关化合物及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2015900507 2015-02-16
AU2015900507A AU2015900507A0 (en) 2015-02-16 Sulfonylureas and related compounds and use of same
PCT/AU2016/050103 WO2016131098A1 (en) 2015-02-16 2016-02-16 Sulfonylureas and related compounds and use of same
CN201680010446.XA CN107428696B (zh) 2015-02-16 2016-02-16 磺酰脲和相关化合物及其用途
CN202110867103.8A CN113582889B (zh) 2015-02-16 2016-02-16 磺酰脲和相关化合物及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680010446.XA Division CN107428696B (zh) 2015-02-16 2016-02-16 磺酰脲和相关化合物及其用途

Publications (2)

Publication Number Publication Date
CN113582889A CN113582889A (zh) 2021-11-02
CN113582889B true CN113582889B (zh) 2024-09-20

Family

ID=56691944

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110867103.8A Active CN113582889B (zh) 2015-02-16 2016-02-16 磺酰脲和相关化合物及其用途
CN201680010446.XA Active CN107428696B (zh) 2015-02-16 2016-02-16 磺酰脲和相关化合物及其用途
CN202110865543.XA Pending CN113563264A (zh) 2015-02-16 2016-02-16 磺酰脲和相关化合物及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201680010446.XA Active CN107428696B (zh) 2015-02-16 2016-02-16 磺酰脲和相关化合物及其用途
CN202110865543.XA Pending CN113563264A (zh) 2015-02-16 2016-02-16 磺酰脲和相关化合物及其用途

Country Status (30)

Country Link
US (4) US10538487B2 (enExample)
EP (3) EP3888749A1 (enExample)
JP (2) JP6929792B2 (enExample)
KR (2) KR20240162585A (enExample)
CN (3) CN113582889B (enExample)
AU (3) AU2016222278B2 (enExample)
CA (2) CA3250390A1 (enExample)
CL (2) CL2017002097A1 (enExample)
CY (1) CY1122832T1 (enExample)
DK (2) DK3578547T3 (enExample)
ES (2) ES2777626T3 (enExample)
HR (2) HRP20200214T1 (enExample)
HU (1) HUE055755T2 (enExample)
IL (2) IL273065B2 (enExample)
LT (2) LT3259253T (enExample)
MA (3) MA47440B1 (enExample)
MD (1) MD3259253T2 (enExample)
ME (1) ME03737B (enExample)
MX (2) MX2017010528A (enExample)
MY (2) MY193765A (enExample)
NZ (1) NZ733948A (enExample)
PE (2) PE20180160A1 (enExample)
PL (2) PL3578547T3 (enExample)
PT (2) PT3578547T (enExample)
RS (2) RS60048B1 (enExample)
RU (1) RU2739356C2 (enExample)
SG (2) SG11201706664QA (enExample)
SI (2) SI3259253T1 (enExample)
SM (1) SMT202000192T1 (enExample)
WO (1) WO2016131098A1 (enExample)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY193765A (en) * 2015-02-16 2022-10-27 Univ Queensland Sulfonylureas and related compounds and use of same
FR3046933B1 (fr) * 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
US11858922B2 (en) * 2016-02-16 2024-01-02 The University Of Queensland Sulfonylureas and related compounds and use of same
JP7050751B2 (ja) 2016-04-18 2022-04-08 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
WO2018103583A1 (en) * 2016-12-05 2018-06-14 Zibo Anxuan Pharmaceutical Science And Technology Co., Ltd. N-hydroxy-benzene-sulfonamide derivatives and their uses thereof
JP7163293B2 (ja) 2017-01-23 2022-10-31 ジェネンテック， インコーポレイテッド インターロイキン－１活性の阻害剤としての化学化合物
GB2561540A (en) 2017-03-13 2018-10-24 Nodthera Ltd Chemical compounds
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
US11236045B2 (en) 2017-06-09 2022-02-01 Cadila Healthcare Limited Substituted sulfoximine compounds
HRP20220195T1 (hr) * 2017-07-07 2022-04-15 Inflazome Limited Novi spojevi sulfonamid karboksamida
WO2019008029A1 (en) * 2017-07-07 2019-01-10 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
CN111793060B (zh) * 2017-07-14 2023-06-06 先天肿瘤免疫公司 Nlrp3调节剂
EP3658538B1 (en) * 2017-07-24 2023-04-19 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
CN117209447A (zh) 2017-07-24 2023-12-12 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
GB201712282D0 (en) * 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
DE102017118230B4 (de) * 2017-08-10 2021-04-22 Christoph Lucks Verfahren zur Analyse und/oder Überwachung von Brücken sowie entsprechendes System und entsprechende Verwendung
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
CN111132974B (zh) * 2017-08-15 2023-11-21 英夫拉索姆有限公司 新颖的磺酰胺羧酰胺化合物
PE20200758A1 (es) 2017-08-15 2020-07-27 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3
EP3668840A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3668843A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
EP3668862A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3668601A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019068772A1 (en) * 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS
WO2019092172A1 (en) * 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CA3078195A1 (en) * 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019092171A1 (en) * 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
WO2019166633A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Sulfonamide derivates as nlrp3 inhibitors
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
EP3759090A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US20200399242A1 (en) * 2018-03-02 2020-12-24 Inflazome Limited Novel compounds
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2019182981A1 (en) 2018-03-21 2019-09-26 Olatec Therapeutics Llc Methods for treating melanoma
GB201806578D0 (en) * 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
ES3038908T3 (en) * 2018-04-23 2025-10-15 Corcept Therapeutics Inc Methods of preparing regioselective n-alkyl triazoles
US20210261512A1 (en) 2018-05-04 2021-08-26 Inflazome Limited Novel compounds
CN108404117B (zh) * 2018-05-29 2020-06-30 广东龙帆生物科技有限公司 核苷酸结合寡聚化结构域样受体蛋白在治疗寨卡病毒感染药物中的应用
CA3103664A1 (en) * 2018-07-03 2020-01-09 Novartis Ag Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
JP2021529187A (ja) 2018-07-03 2021-10-28 ノバルティス アーゲー Ｎｌｒｐモジュレータ
US20210395241A1 (en) * 2018-07-03 2021-12-23 Novartis Ag Nlrp modulators
CA3104199A1 (en) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonylurea compounds as inhibitors of interleukin-1 activity
PE20211811A1 (es) * 2018-07-20 2021-09-14 Hoffmann La Roche Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
PE20211333A1 (es) 2018-08-15 2021-07-22 Inflazome Ltd Compuestos de sulfonamidaurea novedosos
GB201817038D0 (en) * 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
JP2022505525A (ja) * 2018-10-24 2022-01-14 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
US12134611B2 (en) 2018-11-13 2024-11-05 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
CN120531732A (zh) * 2018-11-13 2025-08-26 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
ES2974842T3 (es) * 2018-11-13 2024-07-01 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp
CN113227055A (zh) * 2018-11-16 2021-08-06 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
US20230051589A1 (en) * 2018-11-16 2023-02-16 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
GB201819083D0 (en) * 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
CN113474333B (zh) * 2019-01-14 2025-06-13 载度思生命科学有限公司 新的经取代的磺酰脲类衍生物
WO2020154321A1 (en) * 2019-01-22 2020-07-30 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity
SG11202107653RA (en) * 2019-01-25 2021-08-30 Nodthera Ltd Carbamate derivatives and uses thereof
KR102841700B1 (ko) 2019-02-22 2025-08-01 피아이 인더스트리스 엘티디. 안트라닐산 디아미드 화합물 및 그의 중간체의 합성 방법
EP3934636A1 (en) * 2019-03-06 2022-01-12 Institut National de la Santé et de la Recherche Médicale (INSERM) Inhibitors of ngal protein
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
CN111848461A (zh) * 2019-04-29 2020-10-30 苏州大学 Nlrp3炎症小体抑制剂及其制备方法和应用
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
SMT202400291T1 (it) 2019-06-12 2024-09-16 Nodthera Ltd The Mansion Derivati di solfonilurea e loro usi
EP3983388A1 (en) * 2019-06-12 2022-04-20 Nodthera Limited Sulfonamide derivatives and uses thereof
US20220378801A1 (en) 2019-06-21 2022-12-01 Ac Immune Sa Novel compounds
WO2021002887A1 (en) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy
CA3151865A1 (en) * 2019-07-17 2021-01-21 Zomagen Biosciences Ltd N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as nlpr3 modulators for the treatment of multiple sclerosis (ms)
JP7595642B2 (ja) * 2019-07-17 2024-12-06 ズーマゲン バイオサイエンシーズ エルティーディー Ｎｌｒｐ３モジュレーター
JP2022545400A (ja) * 2019-08-16 2022-10-27 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤として有用な大環状スルホニル尿素誘導体
JP2022547882A (ja) * 2019-09-06 2022-11-16 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤
EP4027986A4 (en) 2019-09-12 2023-10-04 Zydus Lifesciences Limited NOVEL SUBSTITUTED SULFOXIMINE DERIVATIVES
EP4054564A1 (en) * 2019-11-07 2022-09-14 Inflazome Limited Treatment of autoinflammatory disorders
GB201916237D0 (en) * 2019-11-07 2019-12-25 Inflazome Ltd Novel treatment
WO2021089769A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment and prevention of neuroinflammation or an inflammatory brain disorder
CN114641287A (zh) * 2019-11-07 2022-06-17 英夫拉索姆有限公司 神经退行性病症的治疗和预防
WO2021089781A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment or prevention of psychiatric brain disorders using the nlrp3 inhibitor n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide
WO2021089776A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment and prevention of a traumatic brain disorder
JP7392169B2 (ja) * 2019-11-12 2023-12-05 成都百裕制薬股▲ふん▼有限公司 アミド誘導体及びその調製方法並びに医薬における応用
WO2021111351A1 (en) * 2019-12-03 2021-06-10 Cadila Healthcare Limited Novel substituted sulfonylurea and sulfoximineurea derivatives
WO2021150574A1 (en) * 2020-01-22 2021-07-29 Genentech, Inc. Sulfonimidamide compounds as nlrp3 modulators
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
JP2023513935A (ja) 2020-02-18 2023-04-04 インフレイゾーム リミテッド 化合物
JP2023518044A (ja) 2020-03-16 2023-04-27 ズーマゲン バイオサイエンシーズ エルティーディー Ｎｌｒｐ３モジュレーター
CN111358778A (zh) * 2020-03-17 2020-07-03 中国医科大学附属第一医院 Mcc950在制备预防或治疗阿尔茨海默病的药物中的应用
CN115297855A (zh) 2020-03-19 2022-11-04 索芙特海尔公司 治疗nlrp3相关的疾病的方法
KR20230005320A (ko) * 2020-04-30 2023-01-09 얀센 파마슈티카 엔.브이. 신규 트리아지노인돌 화합물
WO2021249337A1 (zh) 2020-06-11 2021-12-16 南京明德新药研发有限公司 二甲基亚磺酰亚胺衍生物
CA3178361A1 (en) * 2020-06-19 2021-12-23 Emanuele Gabellieri Dihydrooxazole and thiourea derivatives modulating the nlrp3 inflammasome pathway
WO2022022646A1 (zh) * 2020-07-29 2022-02-03 南京明德新药研发有限公司 含硒五元杂芳环化合物
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
CA3191410A1 (en) * 2020-09-04 2022-03-10 Mark G. Bock Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof
WO2022098108A1 (ko) * 2020-11-04 2022-05-12 (주) 업테라 Nlrp3 단백질 분해 유도 화합물
FR3115682B1 (fr) * 2020-11-05 2023-02-24 Roquette Freres Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique
WO2022104102A2 (en) * 2020-11-13 2022-05-19 University Of Miami Materials and methods for treating corneal dysfunction
CA3202544A1 (en) * 2020-11-20 2022-05-27 Denali Therapeutics Inc. Compounds, compositions, and methods
WO2022115417A1 (en) * 2020-11-25 2022-06-02 VenatoRx Pharmaceuticals, Inc. Sulfonyl urea nlrp3 inflammasome inhibitors
KR102802013B1 (ko) * 2021-02-03 2025-05-07 환인제약 주식회사 알츠하이머병 치료를 위한 nlrp3 인플라마좀 소분자 억제제
JP7825294B2 (ja) * 2021-02-10 2026-03-06 ハンジョウ イノゲート ファーマ カンパニー リミテッド Ｎｌｒｐ３阻害剤としての化合物
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022232632A1 (en) * 2021-04-30 2022-11-03 Denali Therapeutics Inc. Compounds, compositions, and methods
IT202100011237A1 (it) * 2021-05-03 2022-11-03 Univ Degli Studi Di Torino Composti inibitori dell’inflammasoma nlrp3 e loro uso
CN116635374B (zh) * 2021-05-10 2025-05-06 康百达（四川）生物医药科技有限公司 酰胺衍生物及其应用
WO2022237782A1 (zh) * 2021-05-10 2022-11-17 成都百裕制药股份有限公司 酰胺衍生物及其应用
WO2022237781A1 (zh) * 2021-05-10 2022-11-17 成都百裕制药股份有限公司 酰胺衍生物及其应用
JP2024524250A (ja) 2021-06-23 2024-07-05 エフ． ホフマン－ラ ロシュ アーゲー １－エチル－ｎ－（（１，２，３，５，６，７－ヘキサヒドロ－ｓ－インダセン－４－イル）カルバモイル）ピペリジン－４－スルホンアミドの結晶性カリウム塩
CN117940120A (zh) * 2021-07-16 2024-04-26 戴纳立制药公司 化合物、组合物和方法
ES2948511A1 (es) * 2021-09-08 2023-09-13 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Derivados de n-sulfonilureas y su uso terapeutico
CN115894478B (zh) * 2021-09-30 2025-04-04 杭州民生药物研究院有限公司 一种新型吡啶并吡唑类杂环化合物及其应用
KR20230066899A (ko) 2021-11-08 2023-05-16 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
CN118355000A (zh) * 2021-12-03 2024-07-16 辰欣药业股份有限公司 二甲基亚磺酰亚胺衍生物的盐型及晶型
US20250109126A1 (en) 2021-12-22 2025-04-03 Ac Immune Sa Dihydro-oxazol derivative compounds
WO2023230002A1 (en) * 2022-05-23 2023-11-30 VenatoRx Pharmaceuticals, Inc. Nlrp3 inflammasome inhibitors
WO2024010772A1 (en) * 2022-07-06 2024-01-11 Kodiak Sciences Inc. Nlrp3 inhibitors
JP2025524640A (ja) 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
CN119998284A (zh) 2022-07-28 2025-05-13 Ac免疫有限公司 新化合物
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
KR20240022938A (ko) 2022-08-12 2024-02-20 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN115772173B (zh) * 2022-12-20 2024-04-16 武汉国粹医药科技有限公司 苯并呋喃类化合物、其制备方法及其应用和抗菌剂
WO2024249539A1 (en) 2023-06-02 2024-12-05 Merck Sharp & Dohme Llc 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
KR20250030934A (ko) 2023-08-25 2025-03-05 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
TW202513060A (zh) * 2023-09-29 2025-04-01 瑞士商諾華公司 用於降低心血管疾病的風險之nlrp3抑制劑
WO2025113692A1 (zh) * 2023-12-01 2025-06-05 拜西欧斯（北京）生物技术有限公司 磺酰脲衍生物及其应用
WO2025133307A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Heterocyclic modulators of the nlrp3 inflammasome pathway
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法
WO2025153625A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025153624A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025163069A1 (en) 2024-01-31 2025-08-07 Ac Immune Sa Novel compounds
CN120463630A (zh) * 2024-02-09 2025-08-12 杭州矩阵生物药业有限公司 具有nlrp3抑制活性的磺酰脲类衍生物及其应用
CN118638081A (zh) * 2024-05-23 2024-09-13 武汉科技大学 磺酰脲类化合物
WO2026001614A1 (zh) * 2024-06-26 2026-01-02 拜西欧斯（北京）生物技术有限公司 一种磺酰脲类化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245490A (zh) * 1997-01-29 2000-02-23 辉瑞大药厂 磺酰脲衍生物及其在白介素－1活性的控制中的用途
WO2001019390A1 (en) * 1999-09-14 2001-03-22 Pfizer Products Inc. Combination treatment with il-1ra and diaryl sulphonyl urea compounds

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797474A (en) 1955-07-20 1958-07-02 Boehringer & Soehne Gmbh Sulphonylurea derivatives
US3242174A (en) 1962-02-06 1966-03-22 Pfizer & Co C 1-(tertiary aminosulfonyl)-3-(hydrocarbon) ureas
US3305556A (en) 1962-11-23 1967-02-21 Pfizer & Co C Novel hypoglycemic agents
NL129208C (enExample) 1965-07-14
CH509991A (de) 1966-08-08 1971-07-15 Hoffmann La Roche Verfahren zur Herstellung von Sulfonamiden
NL131473C (enExample) 1966-10-28
BE754588A (fr) 1969-08-07 1971-02-08 Hoechst Ag Thiophene-sulfonyl-urees et les medicaments qui contiennent cessubstances
FR2063472A5 (enExample) 1969-10-17 1971-07-09 Mercier Pierre
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
AU571869B2 (en) 1983-05-09 1988-04-28 E.I. Du Pont De Nemours And Company Pyridyl- and pyrimidyl- sulphonamides
DE3479213D1 (en) 1983-05-16 1989-09-07 Ciba Geigy Ag Herbicidally active and plant growth regulating pyrimidine derivatives, their preparation and use
JPS6045573A (ja) 1983-08-22 1985-03-12 Nissan Chem Ind Ltd ピラゾ−ルスルホニルウレア誘導体，その製法および該誘導体を含有する選択性除草剤
US4723991A (en) 1984-03-23 1988-02-09 E. I. Du Pont De Nemours And Company Lower alkyl 2-[[N-(3-cyano-pyridin-2-yl)aminocarbonyl]aminosulphonyl]benzoate derivatives having herbicidal activity
US4659369A (en) 1984-08-27 1987-04-21 E. I. Du Pont De Nemours And Company Herbicidal acetals and ketals
AU578307B2 (en) 1984-09-17 1988-10-20 E.I. Du Pont De Nemours And Company Herbicidal pyrazolesulfonamides
FI855180A7 (fi) 1985-01-18 1986-07-19 Nissan Chemical Ind Ltd Pyratsolisulfonamidijohdannainen, menetelmä sen valmistamiseksi ja sitä sisältävä rikkaruohomyrkky.
JPH0720957B2 (ja) 1985-11-26 1995-03-08 日産化学工業株式会社 ピラゾ−ルスルホニルウレア誘導体、製法および除草剤
JP2570686B2 (ja) 1985-12-23 1997-01-08 日産化学工業株式会社 ピラゾ−ル誘導体
US4830660A (en) 1986-06-19 1989-05-16 Nissan Chemical Industries, Ltd. Imidazolesulfonamide derivatives and herbicides
ATE71096T1 (de) 1986-09-26 1992-01-15 Ciba Geigy Ag Aminopyrazinone und aminotriazinone.
US4802908A (en) 1987-01-22 1989-02-07 E. I. Du Pont De Nemours And Company Herbicidal 2-(1H)-pyrazinones
EP0511993A1 (en) 1990-01-22 1992-11-11 E.I. Du Pont De Nemours And Company Herbicidal sulfonylureas
IL98784A0 (en) 1990-07-17 1992-07-15 Lilly Co Eli Heterocyclyl sulfonamide derivatives,process for their preparation and pharmaceutical compositions containing them
ES2095955T3 (es) 1990-08-29 1997-03-01 Du Pont Pirrolsulfonilureas herbicidas.
US5214206A (en) * 1990-11-07 1993-05-25 Warner-Lambert Company Aminosulfonyl urea acat inhibitors
DE4039733A1 (de) 1990-12-13 1992-06-17 Basf Ag Substituierte 5-aminopyrazole
CZ36294A3 (en) 1991-08-19 1994-07-13 Du Pont Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
JPH06510763A (ja) 1991-08-19 1994-12-01 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー アンジオテンシン２受容体遮断イミダゾリノン誘導体
US5169860A (en) * 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
JPH0645573A (ja) 1992-07-23 1994-02-18 Nikon Corp 赤外線固体撮像装置
JPH06199054A (ja) 1992-12-28 1994-07-19 Dainippon Printing Co Ltd 熱転写シート
JPH06199053A (ja) 1992-12-28 1994-07-19 Sankyo Kagaku Kk 感熱転写記録用色素
JPH06199047A (ja) 1993-01-08 1994-07-19 New Oji Paper Co Ltd 感熱記録体
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
WO1997011057A1 (en) 1995-09-22 1997-03-27 E.I. Du Pont De Nemours And Company Arthropodicidal 1,4-dihydropyridines and 1,4-dihydropyrimidines
EP0795548B1 (en) 1995-09-28 2002-07-03 Suntory Limited Quinazoline derivatives and use thereof
WO1997030978A1 (en) * 1996-02-26 1997-08-28 Sumitomo Pharmaceuticals Company, Limited Sulfonylureidopyrazole derivatives
US6022984A (en) 1998-07-27 2000-02-08 Pfizer Inc. Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
JP2000053649A (ja) 1998-08-11 2000-02-22 Sumitomo Pharmaceut Co Ltd スルホニルウレイドピラゾール誘導体
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
EP1161415B1 (en) 1999-03-15 2005-07-13 Axys Pharmaceuticals, Inc. N-cyanomethylamides as protease inhibitors
EP1257550B1 (en) 2000-02-04 2005-11-16 Portola Pharmaceuticals, Inc. Platelet adp receptor inhibitors
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
WO2002094176A2 (en) 2001-05-18 2002-11-28 Solvay Pharmaceuticals Gmbh Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
FI110677B (fi) 2001-10-12 2003-03-14 Jujo Thermal Oy Lämpöherkkä tallennusmateriaali
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
WO2003045400A1 (en) 2001-11-30 2003-06-05 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
AR039891A1 (es) 2002-05-28 2005-03-09 Dimensional Pharm Inc Compuestos tiofen-amidinas, sus composiciones farmaceuticas y su uso para la preparacion de medicamentos para tratar enfermedades y trastornos mediados por c1s
US7294635B2 (en) 2003-10-03 2007-11-13 Portola Pharmaceuticals, Inc. Substituted isoquinolinones
PT1668002E (pt) 2003-10-03 2009-11-25 Portola Pharm Inc 2,4-dioxo-3-quinazolinilarilsulfonilureias
WO2005105777A1 (en) * 2004-05-05 2005-11-10 Pharmacia & Upjohn Company Llc Substituted thiophene amide compounds for the treatment of inflammation
US7205296B2 (en) 2004-09-29 2007-04-17 Portola Pharmaceuticals, Inc. Substituted 2H-1,3-benzoxazin-4(3H)-ones
AR052900A1 (es) 2005-02-11 2007-04-11 Astrazeneca Ab Derivados de tiazol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por ece-1
GB0505539D0 (en) 2005-03-17 2005-04-27 Novartis Ag Organic compounds
DK200600313A (da) 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor
JPWO2007105637A1 (ja) * 2006-03-10 2009-07-30 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
US8486987B2 (en) 2007-11-16 2013-07-16 University Of Medicine And Dentistry Of New Jersey Mechanism-based small-molecule parasite inhibitors
US8211928B2 (en) * 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
CN102791712B (zh) 2010-03-05 2015-07-01 协和发酵麒麟株式会社 吡唑并嘧啶衍生物
WO2012067265A1 (en) * 2010-11-18 2012-05-24 Kyoto University Method for screening drugs for suppressing inflammasome activity
US20140221340A1 (en) 2011-09-02 2014-08-07 Kyowa Hakko Kirin Co., Ltd. Chemokine receptor activity regulator
JP6036193B2 (ja) * 2012-11-09 2016-11-30 国立大学法人富山大学 インフラマソーム活性制御剤
PL221813B1 (pl) 2013-02-22 2016-05-31 Univ Medyczny W Lublinie Pochodne 1-arylo-6-benzenosulfonyloimidazo[1,2-a][1,3,5] triazyny oraz sposób ich otrzymywania
TW201501713A (zh) 2013-03-01 2015-01-16 Kyowa Hakko Kirin Co Ltd 眼炎症性疾病之預防及／或治療劑
CN104513239B (zh) 2014-12-10 2017-08-22 沈阳药科大学 吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用
WO2016119349A1 (zh) 2015-01-29 2016-08-04 中国农业大学 一种磺酰脲类、磺酰胺基甲酸酯类化合物的制备方法
MY193765A (en) 2015-02-16 2022-10-27 Univ Queensland Sulfonylureas and related compounds and use of same
WO2016138473A1 (en) 2015-02-26 2016-09-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
WO2017106957A1 (en) 2015-12-23 2017-06-29 The University Of British Columbia Lipid-linked prodrugs
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
US11858922B2 (en) 2016-02-16 2024-01-02 The University Of Queensland Sulfonylureas and related compounds and use of same
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10138228B2 (en) 2016-05-18 2018-11-27 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use therof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
WO2019008029A1 (en) 2017-07-07 2019-01-10 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
HRP20220195T1 (hr) 2017-07-07 2022-04-15 Inflazome Limited Novi spojevi sulfonamid karboksamida
CN111132974B (zh) 2017-08-15 2023-11-21 英夫拉索姆有限公司 新颖的磺酰胺羧酰胺化合物
CN115134851B (zh) 2018-09-27 2025-08-22 苹果公司 用于针对新空口未许可操作的无线电链路监测和失败的方法、装置和介质
GB201819083D0 (en) * 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245490A (zh) * 1997-01-29 2000-02-23 辉瑞大药厂 磺酰脲衍生物及其在白介素－1活性的控制中的用途
WO2001019390A1 (en) * 1999-09-14 2001-03-22 Pfizer Products Inc. Combination treatment with il-1ra and diaryl sulphonyl urea compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
无;无;《REG,STN ON THE WEB》;19920805;无 *

Also Published As

Publication number Publication date
MA41553A (fr) 2017-12-27
IL273065B2 (en) 2024-01-01
ES2777626T3 (es) 2020-08-05
JP2021185159A (ja) 2021-12-09
US11130731B2 (en) 2021-09-28
US20190359564A1 (en) 2019-11-28
HK1249501A1 (en) 2018-11-02
DK3578547T3 (da) 2021-08-23
DK3259253T3 (da) 2020-04-14
SI3259253T1 (sl) 2020-07-31
CL2017002097A1 (es) 2018-04-27
MX2023001647A (es) 2023-03-16
IL253661A0 (en) 2017-09-28
NZ772349A (en) 2024-02-23
WO2016131098A1 (en) 2016-08-25
EP3259253A4 (en) 2018-07-25
EP3259253B1 (en) 2020-01-15
AU2021258033A1 (en) 2021-11-25
RS62164B1 (sr) 2021-08-31
NZ733948A (en) 2022-02-25
LT3259253T (lt) 2020-04-27
US20180044287A1 (en) 2018-02-15
IL273065A (en) 2020-04-30
RU2017128287A3 (enExample) 2019-08-01
RS60048B1 (sr) 2020-04-30
US10538487B2 (en) 2020-01-21
SI3578547T1 (sl) 2021-09-30
CA2975192A1 (en) 2016-08-25
IL273065B1 (en) 2023-09-01
RU2017128287A (ru) 2019-03-18
JP2018510207A (ja) 2018-04-12
IL253661B1 (en) 2023-09-01
KR20240162585A (ko) 2024-11-15
ES2881228T3 (es) 2021-11-29
JP7566699B2 (ja) 2024-10-15
MA56473A (fr) 2022-05-11
SMT202000192T1 (it) 2020-05-08
HUE055755T2 (hu) 2021-12-28
PL3578547T3 (pl) 2021-12-20
PT3578547T (pt) 2021-06-22
AU2020203464B2 (en) 2021-08-05
RU2739356C2 (ru) 2020-12-23
ME03737B (me) 2021-01-20
EP3259253A1 (en) 2017-12-27
SG11201706664QA (en) 2017-09-28
BR112017017610A2 (pt) 2018-05-08
AU2016222278B2 (en) 2020-07-09
HRP20211225T1 (hr) 2021-11-12
KR102727059B1 (ko) 2024-11-05
KR20170109678A (ko) 2017-09-29
HRP20200214T1 (hr) 2020-08-07
LT3578547T (lt) 2021-08-25
PE20221627A1 (es) 2022-10-19
MY197094A (en) 2023-05-24
MA41553B1 (fr) 2020-04-30
US20240400502A1 (en) 2024-12-05
CA3250390A1 (en) 2025-02-25
MA47440B1 (fr) 2021-08-31
SG10202002599XA (en) 2020-04-29
CL2019000060A1 (es) 2019-05-03
MY193765A (en) 2022-10-27
PE20180160A1 (es) 2018-01-18
AU2016222278A1 (en) 2017-08-10
EP3578547A1 (en) 2019-12-11
CY1122832T1 (el) 2021-05-05
CN113563264A (zh) 2021-10-29
EP3578547B1 (en) 2021-05-26
CN107428696A (zh) 2017-12-01
US20220112159A1 (en) 2022-04-14
MA47440A (fr) 2019-12-11
JP6929792B2 (ja) 2021-09-01
CN107428696B (zh) 2021-08-20
IL253661B2 (en) 2024-01-01
AU2020203464A1 (en) 2020-06-18
PT3259253T (pt) 2020-03-11
EP3888749A1 (en) 2021-10-06
CN113582889A (zh) 2021-11-02
MD3259253T2 (ro) 2020-06-30
WO2016131098A8 (en) 2017-03-16
PL3259253T3 (pl) 2020-09-07
MX2017010528A (es) 2018-11-12

Similar Documents

Publication Publication Date Title
CN113582889B (zh) 磺酰脲和相关化合物及其用途
JP7829604B2 (ja) 複素環式化合物、中間体、その製造方法及び応用
KR102189560B1 (ko) Pde4 의 헤테로아릴 저해제
TWI664165B (zh) 含氮雜環化合物
KR20250170647A (ko) Nlrp3 억제제로서의 피라졸로피리미딘 유도체
RU2795512C2 (ru) Сульфонилмочевины и родственные соединения и их применение
HK40057486A (en) Sulfonylureas and related compounds and use of same
TWI917480B (zh) 用於治療ｔｒｐｍ３介導病症之雜環衍生物
BR112017017610B1 (pt) Composto de fórmula (ii) ou um sal ou solvato farmaceuticamente a c e i t á v e i s d o m e s m o , u s o d o c o m p o s t o o u d o s a l o u s o l v a t o farmaceuticamente aceitáveis e composição farmacêutica
TW202412782A (zh) 用於治療ｔｒｐｍ３介導之病症的吲唑衍生物
HK40061670B (zh) 用於治疗与apj受体活性有关的疾病的化合物和组合物
HK1249501B (en) Sulfonylureas and related compounds and use of same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant